-
Innovation Ranking
NewInnovation Ranking – Faes Farma SA
Faes Farma SA (Faes Farma) develops, manufactures, and commercializes pharmaceutical products and raw materials. The company offers prescription drugs, generic drugs, food supplements, over the counter (OTC) medications, baby foods, skin-care treatment products. It exports raw materials and finishes pharmaceutical products to pharmaceutical companies worldwide. Faes Farma also owns animal nutrition and healthcare company such as Ingaso farm. The company operates manufacturing and R&D center in Leioa, Spain, laboratory, production plants, subsidiaries, and commercial offices in international markets. The company...
-
Company Insights
Innovation and Patenting activity of Faes Farma SA Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Faes Farma SA Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Company Insights
Innovation and Patenting activity of PT Kalbe Farma Tbk Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of PT Kalbe Farma Tbk Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Erdafitinib in Squamous Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Erdafitinib in Squamous Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Erdafitinib in Squamous Non-Small Cell Lung Cancer Drug...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Camrelizumab in Endometrial Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Camrelizumab in Endometrial Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Camrelizumab in Endometrial Cancer Drug Details: Camrelizumab (Airuika) is a humanized monoclonal...
-
Product Insights
Rhino-Conjunctivitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Rhino-Conjunctivitis - Drugs In Development, 2023’, provides an overview of the Rhino-Conjunctivitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Rhino-Conjunctivitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Allergic Rhino-Conjunctivitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Allergic Rhino-Conjunctivitis - Drugs In Development, 2023’, provides an overview of the Allergic Rhino-Conjunctivitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Allergic Rhino-Conjunctivitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Dyspepsia (Indigestion) – Drugs In Development, 2023
Global Markets Direct’s, ‘Dyspepsia (Indigestion) - Drugs In Development, 2023’, provides an overview of the Dyspepsia (Indigestion) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Dyspepsia (Indigestion), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Functional (Non Ulcer) Dyspepsia – Drugs In Development, 2023
Global Markets Direct’s, ‘Functional (Non Ulcer) Dyspepsia - Drugs In Development, 2023’, provides an overview of the Functional (Non Ulcer) Dyspepsia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Functional (Non Ulcer) Dyspepsia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Perennial Allergic Rhinitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Perennial Allergic Rhinitis - Drugs In Development, 2023’, provides an overview of the Perennial Allergic Rhinitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Perennial Allergic Rhinitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...